Trillium Therapeutics Inc TRIL-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 06/15/21 EDT
11.48UNCH (UNCH)
52 week range
7.74 - 27.12

...

Loading . . .
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.48
  • 52 Week High27.12
  • 52 Week High Date11/30/20
  • 52 Week Low7.74
  • 52 Week Low Date07/30/20

Key Stats

  • Market Cap1,003.14M
  • Shares Out103.03M
  • 10 Day Average Volume170,716.55
  • Dividend-
  • Dividend Yield-
  • Beta1.83
  • YTD % Change-38.71

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.48
  • 52 Week High27.12
  • 52 Week High Date11/30/20
  • 52 Week Low7.74
  • 52 Week Low Date07/30/20
  • Market Cap1,003.14M
  • Shares Out103.03M
  • 10 Day Average Volume170,716.55
  • Dividend-
  • Dividend Yield-
  • Beta1.83
  • YTD % Change-38.71

RATIOS/PROFITABILITY

  • EPS (TTM)-0.89
  • P/E (TTM)-12.88
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Trillium Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies....
Jan Skvarka Ph.D.
President
James Parsons CPA
Chief Financial Officer
Address
2488 Dunwin Dr
Mississauga, ON
L5L 1J9
Canada

Top Peers

SYMBOLLASTCHG%CHG
APS
BLU
BELLUS Health Inc
3.45-0.02-0.58%
ABUS
Arbutus Biopharma Corp
3.18-0.22-6.47%
MDNA
Medicenna Therapeutics Corp
3.76-0.12-3.09%
DMAC
DiaMedica Therapeutics Inc
8.63-0.54-5.89%